Webcast ImageWebcast
Adaptimmune at LEERINK Partners 6th Annual Global Healthcare Conference (Replay)
02/15/17 at 1:00 p.m. ET
Adaptimmune at LEERINK Partners 6th Annual Global Healthcare Conference
Wednesday, February 15, 2017 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/09/17Adaptimmune to Participate in Upcoming Investor Conference
PHILADELPHIA and OXFORD, U.K., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’s Chief Financial Officer, will present at the Leerink 6th Annual Global Healthcare Conference on Wednesday February 15, 2017 at 1:00 PM EST (6:00 PM BST). The conference is being held at the Lotte New York Palace Hotel. Adaptimmune’s presentation will be webcast live for investors through the... 
Printer Friendly Version
01/09/17Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has nominated a second target, PRAME (preferentially expressed antigen in melanoma), under the strategic collaboration and licensing agreement between the companies. Adaptimmune will be responsible for PRAME preclinical TCR development and delivery of the IND package to GS... 
Printer Friendly Version
01/09/17Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley, Ph.D. has joined the company as Senior Vice President of Global Bio-Process and Development. Dr. Dudley has been a pioneer in the field of immunotherapy manufacturing, and has developed and implemented innovative early process design with accompanying analytics for multiple therapies. Prior to ... 
Printer Friendly Version
01/09/17Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the US Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for autologous genetically modified T-cells expressing an affinity optimized T-cell receptor (TCR) specific for MAGE-A4 in patients with multiple malignant solid tumors. This will be Adaptimmune’s third... 
Printer Friendly Version